ERCC1 and anemia: Risk of overall anemia inducted by FAC chemotherapy was correlated with the presence of genetic and clinical factors: AKR1C3 rs3209896 heterozygous variant AG (OR 3.00; 1.23–7.26; p = 0.015), ERCC1 rs3212986 genotype GT (OR 2.50; 1.09–5.75; p = 0.030), and number of chemotherapy cycles above six (OR 3.88; 1.48–10.16; p = 0.005) (Table 1).